Tarsons Products Ltd
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
- Market Cap ₹ 1,576 Cr.
- Current Price ₹ 295
- High / Low ₹ 544 / 280
- Stock P/E 52.7
- Book Value ₹ 115
- Dividend Yield 0.68 %
- ROCE %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE SmallCap BSE Allcap BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2024 | TTM | |
---|---|---|---|---|
229 | 301 | 296 | 385 | |
125 | 148 | 196 | 282 | |
Operating Profit | 103 | 153 | 100 | 104 |
OPM % | 45% | 51% | 34% | 27% |
5 | 8 | 11 | 16 | |
Interest | 3 | 4 | 10 | 18 |
Depreciation | 14 | 22 | 40 | 55 |
Profit before tax | 92 | 135 | 61 | 46 |
Tax % | 25% | 25% | 30% | |
69 | 101 | 43 | 30 | |
EPS in Rs | 3,583.25 | 18.92 | 8.01 | 5.62 |
Dividend Payout % | 0% | 0% | 25% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -24% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 0.19 | 11 | 11 | 11 |
Reserves | 244 | 479 | 602 | 603 |
34 | 22 | 269 | 317 | |
18 | 33 | 90 | 123 | |
Total Liabilities | 296 | 544 | 972 | 1,054 |
120 | 189 | 336 | 480 | |
CWIP | 22 | 32 | 267 | 217 |
Investments | 0 | 0 | 0 | 0 |
153 | 323 | 369 | 357 | |
Total Assets | 296 | 544 | 972 | 1,054 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2024 | |
---|---|---|---|
68 | 83 | 103 | |
-64 | -138 | -285 | |
-27 | 130 | 136 | |
Net Cash Flow | -23 | 75 | -47 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2024 | |
---|---|---|---|
Debtor Days | 75 | 79 | 96 |
Inventory Days | 277 | 478 | 572 |
Days Payable | 35 | 75 | 65 |
Cash Conversion Cycle | 317 | 482 | 602 |
Working Capital Days | 108 | 150 | 193 |
ROCE % | 35% |
Documents
Announcements
-
Announcement Under Regulation 30
28 Feb - Company received GST order reducing demand and intends to appeal.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Feb - Schedule of Analyst/Institutional Investor Meeting on March 5, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
20 Feb - Transcripts of Q3 FY25 earnings conference call released.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
17 Feb - Audio recording of investor conference call uploaded.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Feb
Annual reports
Concalls
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Dec 2023TranscriptPPTREC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)